Filter component

France: Biotherapies

Market opportunity: Biotherapies

Key details

Opportunity: Biotherapies

Country: France

Sector: Life sciences

Summary

France was a leader of fine chemical pharmacology in the early 1990s but has not been as focused on the revolution in biotherapy, stem cells and biomarkers.

In 2018, the national public investment bank (BPI) announced it would invest 248 million EUR in French biotech. It also recognised the need to import technologies from international companies.

French companies are looking to world-class MHRA-accredited GMP ATMP manufacturing facilities within Europe to help fill production gaps. Both chemical production and bioproduction are required.

While France leads Europe in terms of the overall volume of clinical trials it conducts, it is ranked fourth in terms of Phase I clinical trials.

Scale of opportunity

In 2018, France imported 19.3 billion EUR in medical products and healthcare – an increase of 3.1% from 2017.

These imports came mainly from Germany (17.6%), Switzerland (13.1%), Belgium (13%), the United States (12.4%) and Ireland (9.6%), but also Scotland (0.8%).

Eligible companies

Scottish companies with innovations in biotherapy, stem cells and biomarkers.

Scottish CROs and CMOs that can address specific gaps in the French ecosystem.

Register your interest

If you are interested in this opportunity and would like to talk to one of our in-market specialists, complete our online form and we'll be in touch.

Register your interest

Register your interest

Get in touch with our in-market specialists to find out more about this export opportunity.